- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05196477
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection (ROCOVI)
Multicentre Non-interventional Retrospective Cohort Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a multicentre retrospective cohort study of patients admitted to hospitals in various Russian Federation cities with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid (RNA) laboratory test for the treatment of severe acute respiratory syndrome. The study used information from primary medical documentation of COVID-19 patients who had underwent diagnostic and therapeutic procedures in accordance with the hospital clinical practice. Clinical and laboratory data was collected and analysed to assess olokizumab safety, investigate other treatments, course and outcomes of the disease.
No additional tests or medical procedures were made as part of this study. If any data collected under the protocol was not available or not collected, they deemed lacking.
Based on the results of preliminary assessment of the number of records from the patients meeting inclusion / exclusion criteria in the clinical sites planning to participate in the project it was planned to include no more than 3000 patients in the study, of which about 1500 would be in the main group (received olokizumab therapy), and 1500 would be in the comparison group. It was planned to conduct an analysis in the general population (including taking into account its balancing using statistical methods, in case of significant differences in the initial characteristics of patients in groups), as well as in a subpopulation selected from pairs formed taking into account the comparability of patients by individual characteristics. In total, it was planned to form at least 200 pairs (or more, if the included population is highly comparable). Participation of several clinics in Russian Federation cities (not more than 10 cites) was expected to assure sufficient population for the study.
Data collection period for each hospitalised patient was equivalent to in-hospital period for the treatment of SARS-CoV-2 infection. Data collection by patients was made during hospital stay, including the day of discharge (treatment outcome or lethal outcome). The primary study variables were defined during 21-day observation period.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Chelyabinsk, Russian Federation, 454021
- State Budgetary Healthcare Institution "Regional Hospital № 3"
-
Moscow, Russian Federation, 105187
- State Budgetary Healthcare Institution "City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department"
-
Saint Petersburg, Russian Federation, 197706
- St. Petersburg State Budgetary Healthcare Institution "City Hospital No. 40 of the Kurortny District"
-
Tver, Russian Federation, 170036
- State Budgetary Institution of Healthcare of Tver region "Regional clinical hospital"
-
-
Tatarstan
-
Kazan, Tatarstan, Russian Federation, 420012
- Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" under the Ministry of Health of the Russian Federation
-
-
The Republic Of Bashkortostan
-
Ufa, The Republic Of Bashkortostan, Russian Federation, 450008
- Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University of the Ministry for Healthcare of the Russian Federation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Confirmed diagnosis of SARS-CoV-2 (using virus ribonucleic acid polymerase chain reaction (RNA PCR) test).
- Hospital admission for COVID-19 therapy.
- Infiltrative lung changes based on imaging findings (chest X-ray, chest computed tomography (CT)).
Indications for Preemptive anti-inflammatory therapy (PAT), including two or more signs below:
- reduced oxygen saturation of the blood SpO2 ≤ 97 %
- C-reactive protein (CRP) > 15 mg/L
- body temperature > 37.5 °C for at least 3 days
- white blood cell count < 4.0 x 10^9/L
- absolute lymphocyte count < 2.0 x 10^9/L.
- Olokizumab therapy - for the test group.
- Source medical documents contain the information required for the study (lacking or incomplete data on some serum chemistry values are allowed: D-dimer, ferritin, IL-6, procalcitonin).
Exclusion Criteria:
- Inadequate information on patient's characteristics and therapy.
- Lack of documented confirmation of SARS-CoV-2 infection.
- Initiation of mechanical ventilation (MV) from the first day of admission in the control group or before olokizumab administration in the test group.
- Administration of systemic corticosteroids, IL-6, other immunosuppressants or immunoglobulins before hospital admission.
- Lack of indications to PAT
- Administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors - for comparator group.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Olokizumab treatment group
Subjects with the infection caused by SARS-CoV-2 who received olokizumab injection in addition to the standard therapy.
|
The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
|
Standard treatment group
Subjects with the infection caused by SARS-CoV-2 who received the standard therapy without monoclonal antibodies (mAbs).
|
Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients who died during hospital admission due to any reason
Time Frame: up to 21 days
|
The percentage of patients who died during hospital admission due to any reason in each therapy group
|
up to 21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients who required mechanical ventilation or transfer to intensive care unit (ICU), or who died during hospital admission due to COVID-19
Time Frame: up to day 21
|
The percentage of patients who required mechanical ventilation or transfer to ICU, or who died after olokizumab therapy during hospital admission due to COVID-19.
|
up to day 21
|
The percentage of patients who required transfer to ICU
Time Frame: up to day 21
|
The percentage of patients who required transfer to ICU in each therapy group
|
up to day 21
|
The percentage of patients who required transfer to a new type of oxygen support and to an invasive mechanical ventilation (MV)
Time Frame: up to day 21
|
The transfer to a new type of oxygen support means the transfer to a more severe type of oxygen support (the appointment of low-current oxygen to patients who were initially without oxygen support; transfer from low-flow oxygen therapy to high-flow, non-invasive or invasive ventilation; from high-flow oxygen therapy to non-invasive or invasive ventilation; from non-invasive to invasive ventilation).
|
up to day 21
|
Overall hospitalisation period
Time Frame: from admission to discharge from hospital, up to 21 days
|
Overall hospitalisation period duration in each therapy group (in days)
|
from admission to discharge from hospital, up to 21 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL04041090
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Olokizumab
-
UCB Japan Co. Ltd.CompletedRheumatoid ArthritisJapan, Korea, Republic of, Taiwan
-
UCB BIOSCIENCES, Inc.R-PharmTerminatedRheumatoid ArthritisJapan, Korea, Republic of, Taiwan
-
UCB BIOSCIENCES, Inc.R-PharmTerminatedRheumatoid ArthritisUnited States, Belgium, United Kingdom
-
R-Pharm International, LLCIQVIA Pvt. Ltd; OCT Clinical TrialsCompletedRheumatoid ArthritisKorea, Republic of, United States, Germany, Hungary, Bulgaria, Poland, Taiwan, Mexico, Czechia, Argentina, United Kingdom, Belarus, Brazil, Colombia, Estonia, Latvia, Lithuania, Russian Federation
-
UCB BIOSCIENCES GmbHWithdrawn
-
R-Pharm International, LLCData Management 365; K-Research, LLCCompleted
-
R-Pharm International, LLCQuintiles, Inc.; OCT Clinical TrialsCompletedRheumatoid ArthritisUnited States, Germany, Korea, Republic of, Bulgaria, Poland, Taiwan, Mexico, Hungary, Czechia, United Kingdom, Lithuania, Argentina, Brazil, Colombia, Estonia, Latvia, Russian Federation, Romania
-
R-PharmFederal Budget Institution of Science "Central Research Institute of Epidemiology... and other collaboratorsActive, not recruiting
-
R-Pharm International, LLCQuintiles, Inc.; OCT Clinical Trials; Mene ResearchCompletedRheumatoid ArthritisUnited States, Korea, Republic of, Germany, Czechia, Mexico, Hungary, Poland, Argentina, Brazil, Colombia, Russian Federation